If you were skimming headlines this week, the line that jumped out on Madrigal Pharmaceuticals was simple enough. Rezdiffra has cleared US$1.1b in net sales over the past 12 months and the broader MASH pipeline is filling out. Holding Madrigal Pharmaceuticals over the past year would have meant a 22.8% loss, including dividends. If you had put money in a year ago on the November 2025 record, how should today’s mix of blockbuster sales, whistleblower claims, and expanding trials update your view of what comes next?
The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.
Madrigal Pharmaceuticals has already moved. Pinpoint other ways to investigate the theme among 38 healthcare AI stocks.
The shares cost US$515 at the start of the period, which meant anyone looking at Madrigal Pharmaceuticals had to decide whether current expectations already reflected the big MASH opportunity or still left room for surprise.
The bullish narrative put Fair Value at US$567 and rested on rapid Rezdiffra uptake, with revenue growth assumptions of 91.7% a year and profit margins shifting from a loss to 40.7% over roughly three years.
The more cautious case pointed to a Fair Value of US$482 and stressed dependence on one drug, with assumed revenue growth of 67.2% a year and profit margins improving to 30.8% while facing rising competition and reimbursement pressure.
The key fact is that Madrigal Pharmaceuticals turned a quarterly loss into a profit, with net income shifting from a loss of US$114.19m in Q3 2025 to a profit of US$55.442m in Q3 2026. Revenue rose from US$287.268m to US$431.268m and net margin moved from a 39.8% loss to a 12.9% gain, which supported more of the bullish case, although whistleblower investigations challenged confidence around Rezdiffra data quality.
The useful lesson is that bold profit and margin assumptions need checking against actual net income and net margin, not just sales headlines. When you assess another biotech, track whether reported margins are steadily moving toward what the upbeat scenario required or stalling while revenue stories sound exciting.
Madrigal Pharmaceuticals now trades at US$427, with investors sitting on a 22.8% loss over the past year. The analyst consensus Narrative on Simply Wall St sees Fair Value above that quote and leans on Rezdiffra’s current MASH position, patent runway and the firm’s move into self funded profitability.
The same Narrative stresses that a buyer today is really judging whether broader F4c use, combinations and patient penetration can justify treating this pullback as a chance rather than a warning about single drug reliance and future pricing pressure.
"The rapid uptake and long term patent protection of Rezdiffra, now supported by additional Orange Book listed patents and guidance that coverage is expected into 2045, reinforces the potential for Madrigal Pharmaceuticals to maintain protected revenue and support gross margin strength for an extended period."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.
That is three of the list. See every one of the 35 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com